Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

1.8K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.8K
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

726
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
726
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

540
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
540
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

677
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
677
Lipid Catabolism01:25

Lipid Catabolism

1.3K
Triglycerides serve as crucial long-term energy storage molecules in microorganisms, providing a dense source of metabolic energy. Their breakdown is mediated by lipases, which hydrolyze triglycerides into glycerol and free fatty acids. Each of these components follows distinct metabolic pathways, ultimately contributing to ATP synthesis and cellular energy homeostasis.Glycerol MetabolismGlycerol, released from triglyceride hydrolysis, is phosphorylated by glycerol kinase to form...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrative omics identifies conserved and pathogen-specific responses of sepsis-causing bacteria.

Nature communications·2023
Same author

Effect of Lipoprotein(a) on the Diagnosis of Familial Hypercholesterolemia: Does It Make a Difference in the Clinic?

Clinical chemistry·2019
Same author

A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: The Sino-Roman Study.

Journal of clinical lipidology·2019
Same author

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.

Cardiovascular diabetology·2019
Same author

Impact of PCSK9 inhibitors on plasma lipoprotein(a) concentrations with or without a background of niacin therapy.

Journal of clinical lipidology·2019
Same author

Status of PCSK9 Monoclonal Antibodies in Australia.

Heart, lung & circulation·2019

Related Experiment Video

Updated: Mar 9, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.6K

A Web-Based Registry for Familial Hypercholesterolaemia.

Kathryn R Napier1, Jing Pang2, Leanne Lamont3

  • 1Centre for Comparative Genomics, Murdoch University, Perth, WA, Australia.

Heart, Lung & Circulation
|January 10, 2017
PubMed
Summary
This summary is machine-generated.

Familial hypercholesterolaemia (FH), a genetic disorder causing early heart disease, often goes undiagnosed and undertreated. The FH Australasia Network Registry improves care through standardized data collection for better patient outcomes.

Keywords:
Disease registryFamilial hypercholesterolaemiaInteroperableModel of careOpen sourceRegistry framework

More Related Videos

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

30.8K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.2K

Related Experiment Videos

Last Updated: Mar 9, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.6K
Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

30.8K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.2K

Area of Science:

  • Cardiovascular Medicine
  • Genetics
  • Public Health

Background:

  • Familial hypercholesterolaemia (FH) is a prevalent and severe monogenic disorder of lipoprotein metabolism.
  • It significantly increases the risk of premature coronary heart disease.
  • Many FH patients are currently under-treated and remain undiagnosed, highlighting a critical gap in care.

Purpose of the Study:

  • To introduce the FH Australasia Network Registry as a key element in a comprehensive care model for FH.
  • To establish a standardized, high-quality, and cost-effective system for FH care in the Australasia-Pacific region.
  • To improve patient outcomes through enhanced management of FH.

Main Methods:

  • The FH Australasia Network Registry was developed using an open-source, interoperable registry framework.
  • This framework allows for efficient customization and dynamic modification of web-based disease registries.
  • The registry facilitates the collation of data for various clinical and research purposes.

Main Results:

  • The registry provides a standardized system for FH care across the Australasia-Pacific region.
  • It enables efficient data collection and management for FH patients.
  • The system is adaptable to evolving registry requirements.

Conclusions:

  • The FH Australasia Network Registry is essential for improving health services for FH patients.
  • It supports clinical service planning, clinical trials, and audits.
  • The registry will inform clinical best practices and enhance patient care for familial hypercholesterolaemia.